Xencor, Inc
A biopharmaceutical company that engineers antibodies and other proteins to treat cancer and autoimmune diseases. Its XmAb platform makes precise "plug-and-play" tweaks to the stem of an antibody, and those engineered designs show up in approved drugs like Ultomiris and sotrovimab, as well as in therapies developed with partners such as Novartis and Amgen. Founded in 1997 by scientist Bassil Dahiyat in California, the company also runs its own pipeline of drug candidates.
Granted 704.9K · Sold 325.4K
Granted 430.1K · Sold 268.4K
Granted 35.2K · Sold 11.4K
Granted 84.1K · Sold 21.8K
Granted 83.7K · Sold 9.8K
Granted 48.2K · Sold 13.8K
Granted 58.9K · Sold 11.9K
Granted 19.7K
Granted 39.4K · Sold 23.9K
Granted 39.7K · Sold 25.0K
Granted 24.7K · Sold 11.0K
Granted 13.7K
Granted 24.7K · Sold 12.3K
Granted 24.7K · Bought 53 · Sold 13.4K
Granted 11.0K · Sold 2.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Dahiyat Bassil IPRESIDENT & CEO, Director · 29 transactions | +235% | 546.3K | 704.9K | — | 325.4K |
| Desjarlais John RSR. VICE PRESIDENT & CSO · 30 transactions | +158.1% | 263.8K | 430.1K | — | 268.4K |
| Kuch John JSR. VICE PRESIDENT & CFO · 18 transactions | +10.7% | 121.1Kas of Mar 2024 | 35.2K | — | 11.4K |
| Eckert CeliaSVP, GENERAL COUNSEL · 16 transactions | +708.2% | 76.9K | 84.1K | — | 21.8K |
| Cornelissen Bart JanSR. VICE PRESIDENT & CFO · 6 transactions | — | 75.9K | 83.7K | — | 9.8K |
| Yang AllenSR. VICE PRESIDENT & CMO · 7 transactions | +94.8% | 73.4Kas of Mar 2023 | 48.2K | — | 13.8K |
| Valente NancyEVP, Chief Development Officer · 5 transactions | — | 49.2Kas of May 2025 | 58.9K | — | 11.9K |
| Klencke BarbaraDirector · 2 transactions | — | 19.7Kas of Jun 2025 | 19.7K | — | — |
| Montgomery Alan BruceDirector · 12 transactions | — | 15.5K | 39.4K | — | 23.9K |
| Gustafson Kurt ADirector · 8 transactions | — | 14.7K | 39.7K | — | 25.0K |
| Ranieri Richard JDirector · 6 transactions | — | 13.7K | 24.7K | — | 11.0K |
| Simpson Todd EDirector · 1 transaction | — | 13.7Kas of Jun 2025 | 13.7K | — | — |
| Feigal EllenDirector · 6 transactions | — | 12.3K | 24.7K | — | 12.3K |
| Gorman Kevin CharlesDirector · 7 transactions | — | 11.4K | 24.7K | 53 | 13.4K |
| Rosa-Bjorkeson DagmarDirector · 3 transactions | — | 8.5Kas of Sep 2024 | 11.0K | — | 2.5K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -750.5K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.